GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vetoquinol SA (XPAR:VETO) » Definitions » Capital Expenditure

Vetoquinol (XPAR:VETO) Capital Expenditure : €-19.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Vetoquinol Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Vetoquinol's cash flow for capital expenditures for the six months ended in Dec. 2023 was €-9.3 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was €-19.01 Mil.

Vetoquinol Capital Expenditure Historical Data

The historical data trend for Vetoquinol's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vetoquinol Capital Expenditure Chart

Vetoquinol Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.33 -145.46 -32.40 -22.50 -19.01

Vetoquinol Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.66 -8.82 -13.68 -9.71 -9.30

Vetoquinol Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-19.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vetoquinol (XPAR:VETO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vetoquinol SA (XPAR:VETO) » Definitions » Capital Expenditure
Comparable Companies
XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB BOM:532321 TSE:4507 HKSE:03692 VTRS TSE:4523
Traded in Other Exchanges
8JM:Germany
Address
Magny-Vernois, BP 189, Lure cedex, FRA, 70204
Website
http://www.vetoquinol.com
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.

Vetoquinol (XPAR:VETO) Headlines

No Headlines